NEW YORK (GenomeWeb News) – BG Medicine has filed a preliminary prospectus with the US Securities and Exchange Commission for a proposed initial public offering.

Though the biomarker-development firm did not disclose a price range for shares in the offering, or the anticipated number of shares it will offer, it said that the proposed maximum funds it would seek to raise is a little more than $86 million. BG has proposed that its stock trade on the Nasdaq Global Market under ticker symbol "BGMD."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.